These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23814163)

  • 21. Standing on the shoulders of giants.
    Turajlic S
    Nat Med; 2019 Mar; 25(3):357. PubMed ID: 30842663
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
    Chuk MK; Chang JT; Theoret MR; Sampene E; He K; Weis SL; Helms WS; Jin R; Li H; Yu J; Zhao H; Zhao L; Paciga M; Schmiel D; Rawat R; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Oct; 23(19):5666-5670. PubMed ID: 28235882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
    Ascierto PA; Simeone E; Sileni VC; Del Vecchio M; Marchetti P; Cappellini GC; Ridolfi R; de Rosa F; Cognetti F; Ferraresi V; Testori A; Queirolo P; Bernengo MG; Guida M; Galli L; Mandalà M; Cimminiello C; Rinaldi G; Carnevale-Schianca F; Maio M
    Cancer Invest; 2014 May; 32(4):144-9. PubMed ID: 24484235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
    Jarkowski A; Norris L; Trinh VA
    Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 28. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
    van Rooij N; van Buuren MM; Philips D; Velds A; Toebes M; Heemskerk B; van Dijk LJ; Behjati S; Hilkmann H; El Atmioui D; Nieuwland M; Stratton MR; Kerkhoven RM; Kesmir C; Haanen JB; Kvistborg P; Schumacher TN
    J Clin Oncol; 2013 Nov; 31(32):e439-42. PubMed ID: 24043743
    [No Abstract]   [Full Text] [Related]  

  • 29. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
    Schadendorf D
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
    [No Abstract]   [Full Text] [Related]  

  • 30. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 31. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma.
    Ezra N; Hamid O; Behroozan D
    Dermatol Surg; 2012 Jul; 38(7 Pt 1):1086-90. PubMed ID: 22563699
    [No Abstract]   [Full Text] [Related]  

  • 32. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
    Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
    Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.
    Dean E; Lorigan P
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1437-48. PubMed ID: 23249108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ipilimumab for patients with advanced mucosal melanoma.
    Postow MA; Luke JJ; Bluth MJ; Ramaiya N; Panageas KS; Lawrence DP; Ibrahim N; Flaherty KT; Sullivan RJ; Ott PA; Callahan MK; Harding JJ; D'Angelo SP; Dickson MA; Schwartz GK; Chapman PB; Gnjatic S; Wolchok JD; Hodi FS; Carvajal RD
    Oncologist; 2013 Jun; 18(6):726-32. PubMed ID: 23716015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma BRAF fusions--letter.
    Botton T; Yeh I; Bastian BC
    Clin Cancer Res; 2014 Dec; 20(24):6631. PubMed ID: 25512635
    [No Abstract]   [Full Text] [Related]  

  • 37. Melanoma BRAF fusions--response.
    Hutchinson KE; Ross JS; Stephens PJ; Miller VA; Sosman JA; Pao W
    Clin Cancer Res; 2014 Dec; 20(24):6632. PubMed ID: 25512636
    [No Abstract]   [Full Text] [Related]  

  • 38. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
    Luke JJ; Ott PA
    Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAF
    Beaver JA; Theoret MR; Mushti S; He K; Libeg M; Goldberg K; Sridhara R; McKee AE; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Jul; 23(14):3479-3483. PubMed ID: 28073844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
    Büyükkapu Bay S; Kebudi R; Zülfikar B
    Melanoma Res; 2019 Feb; 29(1):99-101. PubMed ID: 30376464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.